{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+IB&page=11", "query": { "condition": "Phase IB", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 1612, "total_pages": 162, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+IB&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+IB&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T13:04:32.380Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04910568", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cevostamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2021-07-26", "completion_date": "2028-12-21", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-11-06T13:04:32.380Z", "location_count": 6, "location_summary": "Duarte, California • Irvine, California • Denver, Colorado + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04910568" }, { "nct_id": "NCT00373425", "title": "A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OSI Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1252, "start_date": "2006-09", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2015-09-17", "last_synced_at": "2026-11-06T13:04:32.380Z", "location_count": 149, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 122 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00373425" }, { "nct_id": "NCT01822613", "title": "Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "LJM716", "type": "DRUG" }, { "name": "BYL719", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2013-07-26", "completion_date": "2016-06-03", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-11-06T13:04:32.380Z", "location_count": 3, "location_summary": "Chicago, Illinois • Detroit, Michigan • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01822613" }, { "nct_id": "NCT01390818", "title": "Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor", "Breast Cancer", "Non Small Cell Lung Cancer", "Melanoma", "Colorectal Cancer" ], "interventions": [ { "name": "MSC1936369B (pimasertib)", "type": "DRUG" }, { "name": "SAR245409 (PI3K and mTOR inhibitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "82 Years", "sex": "ALL", "summary": "18 Years to 82 Years" }, "enrollment_count": 146, "start_date": "2011-05", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-11-06T13:04:32.380Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01390818" }, { "nct_id": "NCT01471717", "title": "Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "INX-08189 50 mg QD X 5 days", "type": "DRUG" }, { "name": "INX-08189 / Victrelis 800 mg TID X three days", "type": "DRUG" }, { "name": "Victrelis 800 mg TID x 3 days", "type": "DRUG" }, { "name": "Victrelis 800 mg TID with INX-08189 50 mg QD", "type": "DRUG" }, { "name": "Placebo with Victrelis 800 mg", "type": "DRUG" }, { "name": "Cohort 2: Victrelis 800 mg with Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 32, "start_date": "2011-10", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2012-06-22", "last_synced_at": "2026-11-06T13:04:32.380Z", "location_count": 1, "location_summary": "Saint Paul, Minnesota", "locations": [ { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01471717" }, { "nct_id": "NCT03069768", "title": "Stage Ib Trial of mSMART With Varenicline", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nicotine Dependence" ], "interventions": [ { "name": "mSMART", "type": "DEVICE" }, { "name": "Chantix", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2018-04", "completion_date": "2019-06", "has_results": false, "last_update_posted_date": "2018-04-17", "last_synced_at": "2026-11-06T13:04:32.380Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03069768" }, { "nct_id": "NCT06789159", "title": "A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B Cell Lymphoma Refractory", "Diffuse Large B Cell Lymphoma Relapsed", "Epstein-Barr Virus (EBV) Infection" ], "interventions": [ { "name": "VK-2019", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pierluigi Porcu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-08-21", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-11-06T13:04:32.380Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT06789159" }, { "nct_id": "NCT04387071", "title": "CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Malignant Solid Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949", "type": "BIOLOGICAL" }, { "name": "VLP-encapsulated TLR9 Agonist CMP-001", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-04-29", "completion_date": "2022-12-28", "has_results": true, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-11-06T13:04:32.380Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04387071" }, { "nct_id": "NCT03527264", "title": "BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Nivolumab induction", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Nivolumab with chemoradiation", "type": "DRUG" }, { "name": "Nivolumab maintenance", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 4, "start_date": "2018-11-08", "completion_date": "2020-11-13", "has_results": true, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-11-06T13:04:32.380Z", "location_count": 2, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03527264" }, { "nct_id": "NCT00093600", "title": "PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "midostaurin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 69, "start_date": "2004-02", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-11-06T13:04:32.380Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093600" } ] }